Epitopoietic Research
Blood & Organ Banks · New York, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
745 5th Ave Ste 500, New York, New York,...Phone Number
+32 81728610Website
www.erc-immunotherapy.comRevenue
$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
2
1
2
1
About Epitopoietic Research
Epitopoietic Research Corporation (ERC) is a clinical stage biopharmaceutical company focused on developing innovative immunotherapy treatments for cancer, particularly targeting Glioblastoma multiforme (GBM) through its patented Gliovac/ERC1671 vaccine. The company employs a unique approach that utilizes both autologous and allogeneic tumor cells to stimulate the patient's immune system to recognize and eliminate cancer cells. ERC aims to improve patient outcomes by increasing life expectancy and enhancing quality of life while minimizing the side effects associated with traditional cancer treatments. Additionally, ERC is expanding its research to address emerging infectious diseases such as SARS-Cov-2 and Ebola.Explore more
Epitopoietic Research Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Epitopoietic Research your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Epitopoietic Research recently announced quarterly report
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Epitopoietic Research launches new products
Click to see if Epitopoietic Research had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Epitopoietic Research has new funding data
Check out if Epitopoietic Research is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Epitopoietic Research
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Epitopoietic Research, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Epitopoietic Research has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined Epitopoietic Research as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
Epitopoietic Research is experiencing very low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
Epitopoietic Research is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about Epitopoietic Research.
Epitopoietic Research Tech Stack
A closer look at the technologies used by Epitopoietic Research
Epitopoietic Research News & Media
ERC Announces Publication of Positive Efficacy Data with Sitoiganap in Patients with Recurrent Glioblastoma
ISNES, Belgium, June 30, 2022 (GLOBE NEWSWIRE) -- ERC Belgium S.A. (ERC), announced publication of its most recent efficacy data in the May 2022 edition of Frontiers in Oncology. The authors reported striking efficacy and safety of a therapeutic vaccine SITOIGANAP administered to 21 patients with recurrent glioblastoma (rGBM). Glioblastoma has a dismal prognosis with half of rGBM patients dying within 8 months of recurrence of the disease. Data presented by the authors show thatERC-USA Announces FDA Recommendation for Early Termination of Phase 2 Clinical Trial of ERC1671 (Gliovac or Sitoiganap) and Application for Registration Trial for Treatment of Glioblastoma
IRVINE, Calif., April 07, 2021 (GLOBE NEWSWIRE) -- ERC-USA and the University of California, Irvine (UCI), today announce that the FDA has recommended early termination of the onging Phase 2 clinical trial titled ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma in a letter dated April 2, 2021 (https://clinicaltrials.gov/ct2/show/NCT01903330?term=Bota&draw=2&rank=3). The FDA further recommended that the parties pursue a randomized confirmatory Phase 3 registration trial to supporERC Announces Interim Results from Phase 2 Trial of Immunotherapy ERC1671 in Recurrent Glioblastoma Patients
ISNES, Belgium--(BUSINESS WIRE)--ERC Belgium, a clinical-stage biopharmaceutical company developing immunotherapies for the treatment of cancer, has announced promising interim results in the phase 2 clinical trial for ERC1671 (also known as Gliovac or SITOIGANAP) under FDA IND 15430 at the University of California, Irvine Medical Center in Orange, California. The trial, “ERC1671/GM CSF/Cyclophosphamide+Bevacizumab vs Placebo,” is a double-blind, placebo-controlled study of 84 patients with recERC-USA Announces Expansion of Glioblastoma Right-to-Try Treatment for ERC1671 with NYU Winthrop Hospital
PASADENA, Calif.--(BUSINESS WIRE)--ERC-USA, a clinical-stage biopharmaceutical company developing immunotherapies for the treatment of cancer, today announced that NYU Winthrop Hospital (NYU) has agreed to treat one of its recurrent, refractory glioblastoma multiforme (GBM) patients with ERC’s lead therapy, ERC1671, under federal and state Right-to-Try laws (RTT). The expansion of ERC’s RTT program makes its unique immuno-oncology GBM treatment, ERC1671, available to a wider number of patients
Read more news
Top Blood & Organ Banks Companies
See more top companies
Frequently Asked Questions Regarding Epitopoietic Research
Sign Up For FreeTo access detailed company insights
Epitopoietic Research Corporation (ERC) is a clinical stage biopharmaceutical company focused on developing innovative immunotherapy treatments for cancer, particularly targeting Glioblastoma multiforme (GBM) through its patented Gliovac/ERC1671 vaccine. The company employs a unique approach that utilizes both autologous and allogeneic tumor cells... Read More
